Track market-moving stories before they get noisy

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In PicS To Contact Him Directly To Discuss Their Options

If you purchased or acquired PicS Class A Common stock in and/or traceable to PicS' January 30, 2026 initial public offering ("IPO") and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - July 4, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against PicS N.V. ("PicS" or the "Company") (NASDAQ: PICS) and reminds investors of the August 4, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) PicS N.V. had conducted an evaluation of its credit evaluation procedures in December 2025 and determined that such procedures were deficient and in need of enhancement; (2) as a result of the new procedures PicS N.V. had implemented in December 2025, PicS N.V. had reclassified approximately R$590 million of exposures previously classified as Stage 2 to Stage 3, leading to an incremental ECL charge of R$88 million in the three months ended December 31, 2025; (3) PicS N.V. had experienced a heightened, but unreported, Stage 3 formation rate of more than 7% in the fourth quarter of 2025 that deviated substantially from the historical results and trends provided in the offering documents; (4) the IPO's offering documents had materially overstated the quality and ability of PicS N.V.'s credit models and user data to inform PicS N.V.'s underwriting practices and to allow PicS N.V. to timely and effectively monitor, assess, and identify adverse credit events, credit risks, and credit deterioration across its portfolio; and (5) PicS N.V. suffered from degradations in customer credit quality and heightened risks of default and loan impairment as a result of its entrance into materially riskier business lines leading up to the IPO, resulting in undisclosed adverse financial and operational trends such as heightened incidents of default, which predated the IPO and were internally projected by PicS N.V. to continue to worsen following the IPO, materially impairing PicS N.V.'s business, operations, and financial results.

On or around January 29, 2026, PicPay conducted its initial public offering ("IPO"), selling 22.86 million Class A common shares priced at $19.00 per share.

Then, on March 18, 2026, PicPay released its fourth quarter 2025 financial results and revealed that, as part of the Company's "annual review of expected credit loss parameters," it had made several "enhancements" to its Expected Credit Loss ("ECL") calculations, and "implemented a stricter policy to accelerate the classification of renegotiated non-performing exposures from Stage 2 to Stage 3." Consequently, "R$590 million of Stage 2 portfolio balances were reclassified to Stage 3, resulting in an ECL increase of R$88 [$17.56 million USD]." Stage 3 is the Company's highest risk category for its credit portfolio.

On this news, PicPay's stock price fell $3.56 per share, or 22.5%, to close at $12.27 per share on March 19, 2026.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding PicS' conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the PicS N.V. class action, go to www.faruqilaw.com/PICS or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Frequently Asked Questions (FAQ) for Investors Regarding the PicS N.V. Securities Class Action Lawsuit:

What is the PicS N.V. securities fraud lawsuit about?

The PicS N.V. securities fraud lawsuit is a federal securities class action alleging that PicS N.V. (NASDAQ: PICS) and its executives made false and misleading statements to investors in connection with the Company's January 30, 2026 IPO by concealing that the Company had already identified deficiencies in its credit evaluation procedures in December 2025, had reclassified approximately R$590 million of exposures from Stage 2 to Stage 3 (its highest credit risk category) resulting in an incremental expected credit loss charge of R$88 million, and was experiencing a Stage 3 formation rate exceeding 7% in Q4 2025 - a significant deviation from the historical trends presented in the IPO's offering documents. As the truth emerged on March 18, 2026, when PicS disclosed these credit portfolio deteriorations as part of its Q4 2025 financial results, PICS shares fell $3.56 per share, or 22.5%, to close at $12.27 - well below the $19.00 IPO price - causing significant losses for investors.

Who may be eligible to participate in the PicS N.V. class action lawsuit?

Investors who purchased PicS N.V. (PICS) Class A common stock in and/or traceable to the Company's January 30, 2026 initial public offering and suffered financial losses may be eligible to participate in the PicS securities class action. Participation as a class member does not require taking any affirmative legal action; eligible investors may recover losses simply by remaining members of the class. Whistleblowers, former PicS employees, and others with relevant information about the Company's conduct are also encouraged to come forward.

What is a lead plaintiff, and how can I seek appointment in the PicS N.V. lawsuit?

A lead plaintiff in the PicS N.V. class action is a court-appointed investor - typically the one with the largest financial interest in the case - who directs and oversees the litigation on behalf of all class members. Any PicS investor who purchased PICS Class A common stock in or traceable to the IPO may move the Court to serve as lead plaintiff through counsel of their choice. The deadline to seek lead plaintiff appointment is August 4, 2026. Importantly, choosing not to seek the lead plaintiff role does not affect an investor's ability to share in any recovery obtained for the class.

What should investors do if they purchased PicS N.V. stock in the IPO?

Investors who purchased PicS N.V. (PICS) Class A common stock in and/or traceable to the January 30, 2026 IPO and suffered losses should contact Faruqi & Faruqi, LLP immediately to discuss their legal rights. The deadline to seek appointment as lead plaintiff in the PicS N.V. securities class action is August 4, 2026. To speak directly with securities litigation partner Josh Wilson, call 877-247-4292 or 212-983-9330 (Ext. 1310), or visit www.faruqilaw.com/PICS for more information.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/303771

Source: Faruqi & Faruqi LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Peabody Energy To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Peabody Energy between October 14, 2024 and May 4, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - July 4, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Peabody Energy Corporation ("Peabody Energy" or the "Company") (NYSE: BTU) and reminds investors of the August 24, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Peabody Energy's Centurion mine and the multitude of issues causing delays to the ramp-up and the return to full longwall production dates. Such statements absent these material facts caused Plaintiff and other shareholders to purchase Peabody Energy's securities at artificially inflated prices.

On March 30, 2026, Peabody Energy issued a press release lowering guidance pertaining to Centurion mine's expected first quarter 2026 output, announcing that sales volume from the Centurion mine was expected to deliver approximately 250,000 tons in the first quarter due to "greater-than-anticipated mine commissioning challenges" (compared to previous estimates of around 700,000 tons). On this news, Peabody Energy's stock price fell $3.82, or approximately 9.7%, to close at $35.68 per share on March 30, 2026.

On May 5, 2026, Peabody Energy issued a press release disclosing the Company's failure to ramp-up Centurion by the long-awaited March 2026 deadline and cutting guidance related to full year met segment volumes to reflect the increased cost and substantial volume decrease, reducing the full year sales outlook for Centurion to 2.5 million tons compared to the original expectation of 3.5 million tons. On this news, Peabody Energy's stock price fell $1.52, or 5.7%, to close at $25.00 per share on May 5, 2026.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Peabody Energy's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Peabody Energy class action, go to www.faruqilaw.com/BTU or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Frequently Asked Questions (FAQ) for Investors Regarding the Peabody Energy Securities Class Action Lawsuit:

What is the Peabody Energy securities fraud lawsuit about?

The lawsuit alleges that Peabody Energy Corporation (NYSE: BTU) and certain of its officers and directors made materially false and misleading statements and/or concealed material adverse facts concerning the true condition of the Company's Centurion mine, including the nature and severity of issues allegedly causing delays to its ramp-up and return to full longwall production. The complaint alleges that, throughout the Class Period, defendants provided investors with overwhelmingly positive statements about the Centurion mine while purportedly withholding information about the multitude of operational challenges affecting it. These allegedly false and misleading statements are said to have caused investors to purchase Peabody Energy securities at artificially inflated prices. The inflation in the stock price allegedly began to correct when Peabody Energy disclosed, on March 30, 2026, that first quarter 2026 output from the Centurion mine was expected to reach only approximately 250,000 tons — well below prior estimates of approximately 700,000 tons — due to "greater-than-anticipated mine commissioning challenges," and further when the Company disclosed on May 5, 2026 that it had failed to ramp up the mine by its March 2026 deadline and cut its full-year sales outlook for Centurion from 3.5 million tons to 2.5 million tons.

Who may be eligible to participate in the lawsuit?

Investors who purchased or otherwise acquired Peabody Energy Corporation (NYSE: BTU) securities on the NASDAQ between October 14, 2024 and May 4, 2026, inclusive, may be eligible to participate in this lawsuit as members of the proposed class. Eligibility to participate is not limited to investors who seek appointment as lead plaintiff; any qualifying class member may share in any recovery that may ultimately be obtained. Investors who purchased Peabody Energy securities during the Class Period and suffered losses are encouraged to review their transaction records to determine whether they fall within the defined class. Participation in a class action does not require that an investor take any individual legal action or incur separate legal fees to potentially benefit from any recovery achieved on behalf of the class.

What is a lead plaintiff, and how can I seek appointment?

A lead plaintiff is a court-appointed representative who acts on behalf of all class members in directing the litigation, including making key decisions regarding litigation strategy and the selection of lead counsel. Any class member who purchased Peabody Energy securities during the Class Period and suffered a loss may move the court for appointment as lead plaintiff, and courts typically appoint the movant with the largest financial interest in the outcome of the litigation who otherwise satisfies applicable legal requirements. The deadline to file a motion seeking appointment as lead plaintiff is August 24, 2026. Importantly, investors are not required to seek appointment as lead plaintiff in order to participate in the class and share in any recovery that may result from the litigation — class members who do not serve as lead plaintiff retain the ability to benefit from any settlement or judgment.

What should investors do if they purchased Peabody Energy stock during the Class Period?

Investors who purchased Peabody Energy Corporation (NYSE: BTU) securities between October 14, 2024 and May 4, 2026, inclusive, are encouraged to promptly review their brokerage records and account statements to confirm the dates and prices at which they acquired and, if applicable, sold their shares. Investors should take steps to preserve all relevant documentation, including transaction confirmations, account statements, and any communications relating to their Peabody Energy holdings, as such records may be relevant to establishing eligibility and calculating losses. Given that the lead plaintiff motion deadline is August 24, 2026, investors wishing to be considered for appointment as lead plaintiff should act well in advance of that date. Investors may wish to consult with Faruqi & Faruqi, LLP or other qualified securities counsel to evaluate their legal rights and options before the deadline.

Why should investors contact Faruqi & Faruqi, LLP?

Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased Peabody Energy securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/303766

Source: Faruqi & Faruqi LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Graphic Packaging To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Graphic Packaging between February 4, 2025 and February 2, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - July 4, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Graphic Packaging Holding Company ("Graphic Packaging" or the "Company") (NYSE: GPK) and reminds investors of the July 6, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Graphic Packaging was experiencing, inter alia, significant inventory management issues, as well as significantly reduced demand and volumes and increased costs; (2) Defendants downplayed the true scope and severity of the foregoing issues, which were likely to, and did, have a material negative impact on the Company's business and financial results; (3) Defendants likewise overstated the strength and sustainability of the Company's business model and operations, as well as its ability to weather ongoing macroeconomic headwinds; (4) accordingly, the Company's previously issued FY 2025 financial guidance was unreliable and/or unrealistic; and (5) as a result, Defendants' public statements were materially false and misleading at all relevant times.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Graphic Packaging's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Graphic Packaging class action, go to www.faruqilaw.com/GPK or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Frequently Asked Questions (FAQ) for Investors Regarding the Graphic Packaging Holding Company Securities Class Action Lawsuit:

What is the Graphic Packaging securities fraud lawsuit about?

The Graphic Packaging securities fraud lawsuit is a federal securities class action alleging that Graphic Packaging Holding Company (NYSE: GPK) and its executives made false and misleading statements to investors by concealing significant inventory management issues, reduced demand and volumes, and increased costs, while overstating the strength and sustainability of the Company's business model and issuing unreliable financial guidance. As the truth emerged through a series of disclosures — including a May 1, 2025 Q1 earnings miss and sweeping downward revision to FY 2025 guidance, a December 8, 2025 announcement of accelerated inventory reductions, further guidance cuts, and the CEO's departure, and a February 3, 2026 Q4 earnings miss accompanied by a projected meaningful decline in 2026 adjusted EBITDA and the launch of a comprehensive business review — GPK's stock price fell sharply across each disclosure, causing significant cumulative losses for investors.

Who may be eligible to participate in the Graphic Packaging class action lawsuit?

Investors who purchased or acquired Graphic Packaging Holding Company (GPK) stock between February 4, 2025 and February 2, 2026 — the Class Period — and suffered financial losses may be eligible to participate in the Graphic Packaging securities class action. Participation as a class member does not require taking any affirmative legal action; eligible investors may recover losses simply by remaining members of the class. Whistleblowers, former Graphic Packaging employees, and others with relevant information about the Company's conduct are also encouraged to come forward.

What is a lead plaintiff, and how can I seek appointment in the Graphic Packaging lawsuit?

A lead plaintiff in the Graphic Packaging class action is a court-appointed investor — typically the one with the largest financial interest in the case — who directs and oversees the litigation on behalf of all class members. Any Graphic Packaging investor who purchased GPK stock during the Class Period may move the Court to serve as lead plaintiff through counsel of their choice. The deadline to seek lead plaintiff appointment is July 6, 2026. Importantly, choosing not to seek the lead plaintiff role does not affect an investor's ability to share in any recovery obtained for the class.

What should investors do if they purchased Graphic Packaging stock during the Class Period?

Investors who purchased Graphic Packaging Holding Company (GPK) stock between February 4, 2025 and February 2, 2026 and suffered losses should contact Faruqi & Faruqi, LLP immediately to discuss their legal rights. The deadline to seek appointment as lead plaintiff in the Graphic Packaging securities class action is July 6, 2026. To speak directly with securities litigation partner Josh Wilson, call 877-247-4292 or 212-983-9330 (Ext. 1310), or visit www.faruqilaw.com/GPK for more information.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/303762

Source: Faruqi & Faruqi LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

New York, New York--(Newsfile Corp. - July 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Calix, Inc. (NYSE: CALX) between January 28, 2026 and April 21, 2026, inclusive (the "Class Period"), of the important July 27, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Calix securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Calix class action, go to https://rosenlegal.com/cases/calix-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 27, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Calix's first quarter margins had significantly benefited from advanced purchasing of memory components; (2) Calix's advanced supply of memory components was dwindling; (3) as a result, Calix was experiencing negative margin pressure as it was forced to purchase memory components at rising market prices; and (4) as a result of the foregoing, defendants' positive statements about Calix's margins, business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Calix class action, go to https://rosenlegal.com/cases/calix-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/303845

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

, /PRNewswire/ -- 

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Calix, Inc. (NYSE: CALX) between January 28, 2026 and April 21, 2026, inclusive (the "Class Period"), of the important July 27, 2026 lead plaintiff deadline.

So What: If you purchased Calix securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Calix class action, go to https://rosenlegal.com/cases/calix-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 27, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Calix's first quarter margins had significantly benefited from advanced purchasing of memory components; (2) Calix's advanced supply of memory components was dwindling; (3) as a result, Calix was experiencing negative margin pressure as it was forced to purchase memory components at rising market prices; and (4) as a result of the foregoing, defendants' positive statements about Calix's margins, business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. 

To join the Calix class action, go to https://rosenlegal.com/cases/calix-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Badger Meter To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Badger Meter between April 18, 2024 and April 16, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - July 4, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Badger Meter, Inc. ("Badger Meter" or the "Company") (NYSE: BMI) and reminds investors of the August 3, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that Badger Meter's strong financial results reflected "ongoing favorable industry trends," "secular growth drivers," and "solid operating execution." They likewise touted "strong" demand and said they were seeing "robust order pacing and a strong bid pipeline that positions us well for continued sales and earnings growth," and that Badger Meter possessed a "long runway" for growth.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Badger Meter's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Badger Meter class action, go to www.faruqilaw.com/BMI or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Frequently Asked Questions (FAQ) for Investors Regarding the Badger Meter Securities Class Action Lawsuit:

What is the Badger Meter securities fraud lawsuit about?

The Badger Meter securities fraud lawsuit is a federal securities class action alleging that Badger Meter, Inc. (NYSE: BMI) and its executives made false and misleading statements to investors by touting "strong" demand, a "robust" order pipeline, and a "long runway" for growth while concealing that the Company's financial results were not sustainable. As the truth emerged through a series of disclosures — including disappointing Q2 2025 results and a sequential sales decline forecast on July 22, 2025, missed revenue expectations and a 6% sequential decline in utility water sales on January 28, 2026, and Q1 2026 earnings that missed consensus estimates by $0.26 per share with revenue missing by $28.58 million on April 17, 2026 — BMI's stock price dropped sharply, causing significant losses for investors.

Who may be eligible to participate in the Badger Meter class action lawsuit?

Investors who purchased or acquired Badger Meter (BMI) stock between April 18, 2024 and April 16, 2026 — the Class Period — and suffered financial losses may be eligible to participate in the Badger Meter securities class action. Participation as a class member does not require taking any affirmative legal action; eligible investors may recover losses simply by remaining members of the class. Whistleblowers, former Badger Meter employees, and others with relevant information about the Company's conduct are also encouraged to come forward.

What is a lead plaintiff, and how can I seek appointment in the Badger Meter lawsuit?

A lead plaintiff in the Badger Meter class action is a court-appointed investor — typically the one with the largest financial interest in the case — who directs and oversees the litigation on behalf of all class members. Any Badger Meter investor who purchased BMI stock during the Class Period may move the Court to serve as lead plaintiff through counsel of their choice. The deadline to seek lead plaintiff appointment is August 3, 2026. Importantly, choosing not to seek the lead plaintiff role does not affect an investor's ability to share in any recovery obtained for the class.

What should investors do if they purchased Badger Meter stock during the Class Period?

Investors who purchased Badger Meter (BMI) stock between April 18, 2024 and April 16, 2026 and suffered losses should contact Faruqi & Faruqi, LLP immediately to discuss their legal rights. The deadline to seek appointment as lead plaintiff in the Badger Meter securities class action is August 3, 2026. To speak directly with securities litigation partner Josh Wilson, call 877-247-4292 or 212-983-9330 (Ext. 1310), or visit www.faruqilaw.com/BMI for more information.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/303751

Source: Faruqi & Faruqi LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Apple (AAPL +4.88%) is reportedly preparing its most crowded iPhone lineup in years. According to supply chain reports cited by Asian news site Nikkei Asia, the company plans at least five new iPhone models between the back half of 2026 and early 2027, headlined by its first foldable smartphone -- and it has raised the production target for that foldable, rumored to carry a price around $2,500, to about 10 million units, reportedly up from an earlier 7 million to 8 million. The reports helped fuel one of the stock's best sessions of the year.

But the more useful question for shareholders isn't whether a folding iPhone is cool. It's whether a product blitz like this can move the earnings of a tech giant that sells more than 220 million phones a year.

Image source: Apple.

Sizing the foldable opportunity Start with how central the iPhone still is. In Apple's fiscal second quarter (the period ended March 28, 2026), iPhone revenue rose 22% year over year to about $57 billion, a March-quarter record, out of about $111 billion in total sales. That is more than half of the company coming from a single product line.

But how big of a catalyst could a foldable iPhone really be?

Ten million units at about $2,500 works out to around $25 billion of potential revenue in a full year -- a meaningful slice of the more than $200 billion the iPhone generates annually, and mostly a fiscal 2027 story rather than this year's.

Even more, spreading five models across price tiers is a deliberate move to grab share from rivals at both the high and low ends of the market.

Put those pieces together, and the foldable looks less like a blockbuster and more like a halo. It probably won't add much to any single quarter's revenue on its own. What it can do, however, is reset the ceiling on iPhone prices, pulling some upgraders into a pricier tier. In a maturing smartphone market, defending the high end while broadening the lineup to reach more price points could be a serious lever.

Today's Change

(

4.88

%) $

14.36

Current Price

$

308.74

Ultimately, the biggest reason for investors to be upbeat about a busy iPhone product cycle is that it shows that the company is trying to aggressively grow its installed base of active devices -- the foundation of its high-margin services.

And this important segment already has impressive momentum. Services revenue rose 16% to a record $31 billion in the same quarter.

But keep in mind that these new products won't show up in the tech giant's financials for a while. The foldable's revenue mostly lands next year, so this news bears on fiscal 2027's numbers, not the print later this month. Apple reports third-quarter results for fiscal 2026 on July 30, and management has guided for revenue growth of 14% to 17%.

Then there is the stock's price. Shares change hands at about 37 times earnings, a premium that already assumes a strong product cycle.

And there are other risks beyond valuation risk. Apple has never shipped a foldable, and a first-generation product in a brand-new form factor carries real execution risk -- hinges, unique displays, and manufacturing yields are all hard to get right. And even a runaway hit could be capped at a certain volume.

Still, the figure that ultimately moves Apple's earnings over the long haul won't be foldable units. It's total iPhone volume and how many of those buyers deepen their spending on services over time.

Overall, I do think Apple stock looks good here, but reports are still reports. I'd treat the foldable as upside optionality stacked on top of an iPhone-and-services engine that's already growing at a double-digit clip -- a reason to keep owning Apple, but not a reason to chase it on a rumor. With that said, if the rumor proves true, I think fiscal 2027 could be a major year for the company -- and maybe for the stock, too.

Xbox at a gamescom briefing in 2014. Microsoft is pressing its games division to turn a profit. (Microsoft Photo) In 2007, Microsoft’s Xbox 360 consoles started dying — overheating until three lights on the front blinked red, a defect gamers came to call the “red ring of death.” Microsoft’s response was to extend the warranty on every machine and take a charge of more than $1 billion to fix the problem, making it one of the costliest product failures in the company’s history.

Microsoft could afford it financially, but the bigger factor was strategy. Xbox was a bet on the living room, and for a company minting money on Windows and Office at the time, losing a billion or so was a justifiable cost of staying in the game.

Nearly two decades later, that patience has run out.

“Going forward, this cannot continue,” the new Xbox CEO Asha Sharma wrote in a memo to employees last month, offering a blunt assessment of a business that has spent more than $20 billion over five years, only to see its core revenue fall by nearly half a billion dollars, running at a thin 3% profit margin, by Microsoft’s own internal measures.

Asha Sharma took over as CEO of Microsoft’s Xbox business in February. In a memo to employees last month, she wrote that the division’s heavy spending and shrinking revenue “cannot continue.” (Microsoft File Photo) With thousands of layoffs expected to be announced across Microsoft as soon as next week, the Xbox division is likely to be among the hardest hit.

The cuts reach across the company — including sales and consulting — part of a restructuring that has become routine around the close of Microsoft’s fiscal year. But for Xbox, they’re an early step in a broader effort to reset the business, rein in costs, and position the division for healthier profits.

Microsoft CEO Satya Nadella has been blunt about it: the company has spent years subsidizing Xbox rather than profiting from it, and that era is over. The videos and livestreams of people playing Xbox games that fill YouTube generate more money than Microsoft makes from the games themselves, he noted in an appearance on the Hard Fork podcast.

“No one can accuse Microsoft of not having invested for the last 25 years,” Nadella said. “And now we have to turn this into a sustainable business.”

Long-term strategic bet Turning it around means breaking a pattern that runs through Xbox’s entire history.

Xbox launched in 2001 and lost money for most of its first decade. Microsoft absorbed the losses and stayed in — going up against Sony’s PlayStation and Nintendo — because it saw a strategic prize in owning a piece of the living room, and later of mobile. Online gaming also gave the company early experience running services at scale, which fed its cloud ambitions.

Over time, the goal shifted from selling hardware to selling subscriptions.

Xbox Live, launched in 2002, turned online play into recurring revenue. Game Pass, which arrived in 2017, let players pay a monthly fee — the top tier is about $23 — for a library of games, including Microsoft’s own new releases the day they come out. The idea was to get people paying for Xbox everywhere: consoles, PCs, phones and the cloud.

And when growth stalled, Microsoft doubled down. It paid $7.5 billion in 2021 for Bethesda, the studio behind Fallout and The Elder Scrolls, then $69 billion in 2023 for Activision Blizzard (whose games include Call of Duty, World of Warcraft, Diablo and the mobile hit Candy Crush) the largest acquisition in Microsoft’s history.

A series of economic headwinds Microsoft could afford to be patient through all of it. Now it’s not so simple. In recent years, almost everything about the economics of gaming has turned against Xbox at the same time.

Hardware loses money, and AI is making it worse. Microsoft sells consoles at or below cost, banking on games and subscriptions to make up the difference. But AI data centers are consuming so much memory and storage that chip prices have spiked. That has forced Microsoft to raise Xbox console prices, most recently a $100-to-$150 hike this summer that it blamed directly on component costs.

Xbox lost the console war. By most estimates, Sony’s PlayStation 5 has outsold the Xbox Series X and S more than two to one. A smaller base means fewer game sales and subscriptions to offset the upfront hardware losses. That has left Xbox a distant second for the entire generation.

Revenue is shrinking. Even setting aside the games it gained from Activision, Xbox’s annual revenue has fallen nearly $500 million over five years — while the money going into the business keeps climbing. It has been investing more to earn less.

Microsoft’s most recent quarterly filing shows gaming revenue of $16.8 billion for the nine months through March, down about $1.1 billion, or 6%, from a year earlier.

Game Pass cuts into sales. Handing subscribers a new game the day it launches undercuts the roughly $70 they would have paid to buy it. The service delivers steady subscription income, but thinner economics on the games themselves.

Activision didn’t fix the margins. Even with one of gaming’s most profitable businesses folded in, Xbox earns only about 3 cents of profit on every dollar — well under the 17 to 22 cents typical in the industry. If the biggest acquisition in company history can’t move the margin, little will.

Every spare billion is flowing to AI. Microsoft is pouring more than $100 billion a year into the data centers and chips behind its AI push, trying to capitalize on the boom. Against a risk and payoff that big, a gaming business that barely breaks even feels like yesterday’s strategic bet.

What’s next for Xbox The cuts have already started. In recent weeks, Microsoft has signaled plans to close or sell some studios, including Ninja Theory, maker of the acclaimed “Hellblade” series.

Shedding staff, studios and marketing will lift Xbox’s profit margins in the near term. What it won’t do is fix the underlying problem: a business can trim its way to a better number only so much before it has to generate more revenue.

Sharma’s plan, so far, is to concentrate on Xbox’s biggest franchises, funding blockbusters like Halo and Fallout while pulling back elsewhere. It’s leaning on Game Pass and releasing most of its games on PCs and rival consoles from Sony and Nintendo, reaching players well beyond Xbox’s shrinking base, even as it holds back a few new exclusives like Gears of War to give owners a reason to stay.

Microsoft is also rethinking the console itself. In her memo, Sharma described a “hardware component crisis” that has left the company unable to make as many consoles as players want, and called for “a new business model and partnerships” for its hardware.

How far the reset ultimately goes is an open question. The Information reported that Microsoft has weighed making Xbox a standalone subsidiary, a joint venture, or a spin-off, though nothing is imminent.

Microsoft’s response to the Xbox 360 “red ring of death,” July 6, 2007. (Seattle Post-Intelligencer / NewsBank) Whatever happens next, it’s clear that times have changed. In 2007, as the red ring of death crisis emerged, Peter Moore, who ran the Xbox business at the time, and his boss Robbie Bach went to then-CEO Steve Ballmer to ask for the money to repair and replace the failing consoles.

Ballmer didn’t flinch. “What’s it going to cost?” he asked, as Moore later recalled.

Told it was $1.15 billion, Ballmer said, simply: “Do it.”

Moore credits that decision with saving Xbox. There would have been no Xbox One, he said, without Ballmer’s willingness to spend more than a billion dollars to protect the brand.

But nearly two decades later, Microsoft is done writing that kind of check for Xbox.

Nvidia is still the dominant force in its industry. The stock actually looks pretty cheap.

Micron Technology (MU 5.68%) has delivered one of the most explosive performances among semiconductor stocks in 2026. To date, the memory company's shares are up 241% this year, making it the second-highest gainer in the Nasdaq-100.

After such a meteoric rally, most investors might assume the easy money has already been made. But in my view, Micron's true potential is only beginning to unfold. The catalyst that powered its meteoric ascent -- unprecedented demand for advanced memory in artificial intelligence (AI) data centers -- is accelerating, not peaking.

That sets the stage for Micron to enjoy substantially higher earnings power, and puts the stock price on a trajectory that could lead it to trade at $2,000 or more within the next year.

Image source: Micron Technology.

Breaking down Micron's booming business Over the last few quarters, Micron has meaningfully accelerated both its revenue and earnings growth. The reason is simple: The company's products sit at the center of the AI infrastructure build-out. Hyperscalers are pouring record sums of capital expenditures into the construction of new data centers, which has resulted in acute shortages of DRAM, NAND, and high-bandwidth memory (HBM) -- all three of which Micron specializes in.

These shortages are giving Micron significant pricing power in one of the chip market's highest-growth segments. Unlike past cycles for the memory market, where demand was broad and easily satisfied, today's AI-driven demand is concentrated in specific products where Micron holds a strong competitive position alongside SK Hynix and Samsung. The implementation of long-term strategic customer agreements further locks in revenue and profit visibility -- helping reduce the traditional volatility of the memory business.

Taken together, the result is a clear upward trajectory for Micron's top and bottom lines. The narrative for the memory and data storage market is no longer a cyclical story, but rather one of structural expansion in an expanding addressable market. That puts Micron in a powerful position.

Today's Change

(

-5.68

%) $

-58.69

Current Price

$

973.59

Micron's path to $2,000 per share Consensus estimates from Wall Street analysts currently project that Micron's EPS will be $73.32 for the current fiscal year and $149.64 for the next fiscal year. These figures clearly reflect staggering optimism as the AI infrastructure build-out continues.

MU EPS Estimates for Current Fiscal Year data by YCharts.

With that said, Micron stock trades at a modest forward price-to-earnings (P/E) ratio of 6.7. I think that's a conservative level relative to the company's expected earnings growth. Taking the point further, that low multiple could indicate that the market is still pricing Micron as if it were in a cyclical industry, rather than viewing it as a hypergrowth business undergoing a fundamental shift.

I think Micron's current valuation profile leaves significant room for a rerating as the durability of AI-driven memory demand becomes more widely recognized by growth investors. For the stock price to hit $2,000 if the forward P/E holds steady at 6.7 would require next year's EPS to reach about $298. That's essentially a double from Wall Street's already aggressive forecast.

The more realistic path to reaching a $2,000 stock price is for Micron's forward P/E to rise closer to 13. While that would be a meaningful expansion from current levels, investors have seen similar step-ups by other memory and storage stocks, such as Sandisk.

In short, I think Micron's days of trading at a deep cyclical discount are limited. The foundation for meaningful share price appreciation has been set, making such a stock surge not just plausible, but highly probable.

Southeast Asia's Only Hospital Network with Two Hospitals Receiving DistinctionJAKARTA, July 4, 2026 - (ACN Newswire) - Siloam International Hospitals has again

Under the leadership of new CEO Greg Abel, Berkshire Hathaway is making a splash in the technology space. Based on its most recent 13F filing, the conglomerate owned 68,462,015 Class A shares and 17,944,778 Class C shares of Alphabet (GOOGL 0.23%) (GOOG 0.37%) as of March 31, which today is valued at $30.7 billion. These two positions combined make up Berkshire's fourth-largest holding in a single company's equity.

On June 1, however, the Omaha enterprise announced a $10 billion private placement into the "Magnificent Seven" stock. With a total position of nearly $41 billion in Alphabet, this is now a bigger position than Coca-Cola. But it's still smaller than Apple and American Express.

Investors might view these decisions as uncharacteristic of the strategy Berkshire and Warren Buffett have long operated with. This bet makes sense, though.

Here are three possible reasons why the conglomerate is so bullish on Alphabet.

Image source: The Motley Fool.

1. Alphabet is an exceptional business Berkshire's portfolio consists of high-quality names. Alphabet might be the best business among all the holdings.

It operates from a position of financial strength. Revenue rose 22% year over year to $110 billion in the first quarter (ended March 31), an unbelievable gain for a company of this size. Operating income climbed 30% during that period, resulting in a superb 36% operating margin.

Alphabet is a cash machine. In 2025, it raked in $73 billion in free cash flow. Management uses the windfall to pay a small dividend, with capital also directed toward sizable share buybacks.

Buffett coined the phrase "economic moat." Alphabet's moat has proven to be durable over time, protecting its competitive position. The most notable contributor is a network effect. This shows up in the crown jewel Google Search segment. As a two-sided platform, YouTube also benefits from the same attribute.

2. The valuation isn't excessive "It's far better to buy a wonderful company at a fair price than a fair company at a wonderful price," Buffett wrote in Berkshire's 1989 shareholder letter. These words, drafted nearly four decades ago, are still being applied by the conglomerate today. It's almost as if the team at Berkshire read these words before it made the purchases for Alphabet.

Alphabet is an outstanding business, but the valuation hasn't been excessive. Berkshire first bought shares in the third quarter last year. And over the past 12 months, the stock's average price-to-earnings (P/E) ratio is 26.6.

The S&P 500 currently trades at a P/E multiple of 25. Alphabet's slight premium is easily justified.

Today's Change

(

-0.23

%) $

-0.85

Current Price

$

360.36

3. Berkshire is bullish on AI In the past, Berkshire has shied away from allocating significant capital to technology enterprises. It has owned Apple for more than a decade, to be fair. But the market would agree that Alphabet, a dominant internet business, is a pure tech play, given its different operating segments compared to Apple's focus on consumer products and services.

Now that it owns $41 billion in shares, Berkshire is clearly bullish on artificial intelligence (AI). This is obvious, although it might come as a surprise to market observers. The amount of AI-related spending is unprecedented. 

The conglomerate must believe that Alphabet will earn a satisfactory return on the $180 billion to $190 billion in capital expenditures it has planned just in 2026, which will "significantly increase" next year, according to chief financial officer Anat Ashkenazi. The company is involved in many layers of the AI industry, from chips and cloud computing to model development, advertising tools, and user-facing apps. Therefore, it's in a position to monetize all cash outlays.

Berkshire prefers owning stocks forever. Knowing how stringent the filter is for what gets added to the portfolio, the average investor can buy Alphabet shares right now with confidence.

Investors looking for high-yield dividend stocks typically don't expect them to generate alpha. But in some cases, they do. Take Sonoco Products (SON +2.26%), for example.

Sonoco Products is not the oil and gas company, which is spelled differently. Sonoco Products makes packaging -- metal, paper, and plastic packages for consumer and industrial uses.

It's not a stock many people know, but Sonoco is not only paying an above-average dividend yield; it is also beating the S&P 500 and the Nasdaq.

Image source: Getty Images.

Sonoco crushes S&P 500 and Nasdaq Sonoco's stock has posted impressive numbers this year. The stock has returned 30% year to date, beating the Nasdaq's 10.3% and the S&P 500's 8.5%.

Further, the stock has a dividend yield of 3.78%, well above the S&P 500 average. It has also boosted its dividend annually for the past 43 consecutive years. If it keeps boosting the payout annually for seven more years, it will be a Dividend King.

Sonoco Products is coming off a quarter in which sales dropped 2%, but earnings rose 26% year over year to $0.68 per share. This is largely due to an expense-reduction plan that led to a 4% drop in selling, general, and administrative expenses in the latest quarter.

Sonoco's Profitability Performance Plan targets $32 million in savings this year and $150 million to $200 million over the next three years. It is also streamlining operations by selling off some of its lower-performing assets, like ThermoSafe. The expense reductions will offset some of the higher material costs the company is experiencing due to inflation and tariffs.

Today's Change

(

2.26

%) $

1.27

Current Price

$

57.42

Also, net sales will stall out in fiscal 2026, as the company guides for revenue between $7.25 billion and $7.75 billion, which would be on par with last year at the midpoint. Further, cash flow from operations is anticipated to be between $700 million and $800 million, up slightly from last fiscal year.

Sonoco has more room to run Sonoco's stock has rallied this year mainly due to its cost-cutting initiative and the pivot to consumer packaging from industrial. Consumer packaging is a higher-margin business and less cyclical than industrial packaging. The company has been steadily increasing consumer sales, and the consumer side now makes up about 67% of its total sales, up from 42% in 2020.

Sonoco has strong cash flow, a low payout ratio of 38%, and is fully committed to its dividend. It has raised its dividend for 43 straight years and has paid a dividend for 404 straight quarters (since 1925).

While analysts expect only 2% earnings growth in fiscal 2026, they see 10% growth in 2027, likely due to the benefits of the pivot and the Profitability Performance Plan kicking in.

Roughly 50% of analysts rate Sonoco as a buy, while 50% rate it a hold. It has a median price target of $63 per share, which suggests 12% upside.

Plus, the stock is still dirt cheap, even after the 29% surge. It is trading at 9 times forward earnings and has a minuscule five-year PEG ratio of 0.20, which makes it a great value and a good buy -- for both dividends and returns.

CoreWeave (CRWV 4.58%), a neocloud provider of AI infrastructure services, went public at $40 per share on March 28, 2025. By June 20, it had reached a record high of $183.58. But as of this writing, it trades at about $82. Let's see if that pullback is a good buying opportunity.

Image source: Getty Images.

What does CoreWeave do? CoreWeave was originally an Ethereum miner, but it repurposed its GPUs to remotely process AI tasks after the crypto market crashed in 2018. It subsequently expanded its data center count from just three centers at the end of 2022 to 49 centers today, and it supports that infrastructure with more than 250,000 Nvidia (NVDA 1.39%) GPUs.

CoreWeave's AI-optimized servers can handle advanced AI workloads 35 times faster and 80% cheaper than larger cloud infrastructure platforms like Amazon Web Services (AWS) and Microsoft Azure. Its largest customers include Microsoft, Meta (META 4.80%), OpenAI, Anthropic, Nvidia, and the quantitative trading firm Jane Street.

Today's Change

(

-4.58

%) $

-3.92

Current Price

$

81.76

How fast is CoreWeave growing? CoreWeave's revenue surged from $16 million in 2022 to $5.1 billion in 2025. Its backlog swelled to $99.4 billion at the end of the first quarter of 2026, and analysts expect its annual revenue to grow at a three-year CAGR of 99% to $40.3 billion in 2028. That's a jaw-dropping growth rate for a stock that trades at just 3.5 times this year's sales.

However, CoreWeave's net loss also widened from $31 million in 2022 to $1.2 billion in 2025, and analysts expect it to nearly double to $2.2 billion by 2028. It also ended its latest quarter with $50.8 billion in total liabilities, giving it a high debt-to-equity ratio of 10.8. When we include that debt in its enterprise value of $86.3 billion, it looks a bit pricier at 6.8 times this year's sales.

Is CoreWeave's pullback a buying opportunity? CoreWeave has plenty of growth potential, but investors aren't sure it can execute its expansion without breaking the bank. When CoreWeave's stock hit a record high last summer, investors were expecting the Fed to cut interest rates, making it cheaper for the company to expand.

But today, more analysts expect interest rate hikes in the second half of 2026 if inflation doesn't cool off. That's why investors backed away from unprofitable, high-growth companies like CoreWeave. Competition from other neocloud companies and Meta, which recently decided to sell some of its excess cloud computing power, is exacerbating that pressure. However, CoreWeave should become appealing again as interest rates stabilize, it locks in more customers, and economies of scale kick in. So if you're looking for an AI stock to hold for a few years instead of a few quarters, CoreWeave's latest pullback could be a golden buying opportunity.

Leo Sun has positions in Amazon and Meta Platforms. The Motley Fool has positions in and recommends Amazon, Ethereum, Meta Platforms, Microsoft, and Nvidia. The Motley Fool has a disclosure policy.

After a ton of hype and anticipation, Space Exploration Technologies (SPCX +2.83%), aka SpaceX, finally began trading on the public market in June. The stock quickly ran to $225 but has since cooled off and settled in the $150-to-$165 range. It's difficult to know what price the stock might hit by the end of 2026, but there are some potential clues.

It may seem difficult to fathom, but I predict SpaceX could trade down near $100 by the end of 2026. Here's why.

Image source: Getty Images.

SpaceX is approaching a major pivotal moment For starters, SpaceX will likely report earnings for the second quarter sometime in August. It's the first earnings report since the IPO, a crucial moment as it's the first chance investors will have to get a fresh look at SpaceX's ongoing business activities. CEO Elon Musk will have the opportunity to lay out updated guidance and expectations for the business over the coming quarters, and Musk seldom shies away from setting the bar high.

But Wall Street has already set high expectations for SpaceX's stock. Based on the company's 2025 revenue of $18.6 billion, the stock's current market cap of roughly $2.07 trillion values SpaceX at over 111 times sales. Investors will struggle to find an established company's stock that is anywhere near as expensive.

That alone isn't troubling, but the business now has to deliver results to justify such a high price tag.

Can SpaceX fall to $100 per share? It's possible Ultimately, SpaceX's lofty valuation is probably the sticking point investors want to home in on over the second half of 2026. History contains many fresh IPO stocks that struggled under the weight of high expectations, and it wouldn't surprise me at all to see the stock sell off once SpaceX's first earnings report sets new expectations for the coming quarters.

Today's Change

(

2.83

%) $

4.46

Current Price

$

162.00

SpaceX grew revenue by 33% from 2024 to 2025. That's probably not going to cut it for a stock trading at over 100 times its revenue. SpaceX probably needs to accelerate growth. To be clear, that could happen. It has a fresh influx of capital from the IPO and recently announced an agreement to acquire artificial intelligence start-up Anysphere (parent company of AI-powered code editor Cursor) for $60 billion in stock.

But again, the expectations are so incredibly high that it's going to be very difficult to live up to them. SpaceX would still be pricey at 50 times sales. Even if revenue growth accelerated to 50% in 2026 and SpaceX earned $28 billion in sales, that would translate to a market cap of just $1.4 trillion. That's a 36% haircut, pricing shares at approximately $103. That's not even factoring in dilution from the all-stock Anysphere acquisition.

At the end of the day, SpaceX is an exciting company with a tragically expensive stock. It's probably wise to avoid it until the balloon lets out a bit of hot air.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

© William Potter / Shutterstock.com

The REX FANG & Innovation Equity Premium Income ETF (NASDAQ:FEPI) is one of the most aggressive volatility-income products on the market, selling calls against a concentrated basket of AI and mega-cap tech names to fund weekly cash distributions. Recent payouts have run roughly $0.21 per week against a share price of about $42, which annualizes into the ~25% headline yield FEPI is marketed on. The question every holder should be asking is whether that check is real income or the fund quietly returning your own capital.

How FEPI actually generates its yield FEPI holds the roughly 15 constituents of the Solactive FANG Innovation Index and writes short-dated call options against them. The latest NPORT filing shows the fund is net long the underlying stocks with a stack of short calls layered on top: $19.7 million in short call exposure, or about 3% of the $652 million net asset base. Premium collected from those calls is what funds the weekly distribution. FANG here is shorthand for the tech leaders driving the AI cycle, and the top positions reflect it: AMD at 8%, Micron at 8%, Alphabet at 7%, Broadcom at 7%, and NVIDIA at 7%.

The underlying businesses are not the problem NVIDIA (NASDAQ:NVDA) just posted $81.6 billion in Q1 FY27 revenue, up 85% year over year, with $48.6 billion in quarterly free cash flow. Meta Platforms (NASDAQ:META) generated $56.3 billion in Q1 26 revenue at a 41% operating margin. Amazon (NASDAQ:AMZN) grew AWS 28% to $37.6 billion. These are cash-generative businesses with durable earnings, so credit risk in the equity sleeve is minimal. The sustainability risk lives entirely in the options mechanics.

Why the payout math is fragile Two forces determine whether FEPI’s distribution is durable: implied volatility and the direction of the underlyings. The VIX is almost 17, below the trailing 12-month average of about 18 and in the 38th percentile of the past year. Lower volatility means thinner call premiums, which is why the 2026 weekly payouts of $0.20 to $0.22 represent a step down from the richer 2024 monthly distributions that ran $1.08 to $1.19 per share.

Direction is the second problem. When NVIDIA, Meta, or Amazon rally sharply past written strikes, gains get capped and the fund either buys back calls at a loss or lets shares get called away. Prediction markets currently peg a 90% probability that NVDA touches $192 in July and 50% odds of a close above $210, meaning meaningful call-assignment risk is priced in.

The total-return reality check Yield without price performance is an illusion. FEPI is up 3% year to date on a total-return-adjusted basis, while the Nasdaq-100 via QQQ is up 16%. Over the past year, FEPI has returned 18% against QQQ’s 29%. The distributions are being paid, but roughly half of the underlying tech rally has been surrendered to the call-writing overlay. Holding NVIDIA outright would have delivered 24% over one year with no cap.

Error: Invalid chart data JSON

What FEPI is actually good for FEPI’s distribution is safe in the sense that the fund is not on the verge of collapse. Its holdings are the strongest cash flow generators in the market, and the covered-call machine will continue producing premium as long as the underlyings remain volatile. What is at risk is the level of the payout and the NAV supporting it. The 2024 monthly distributions were roughly $13 per year in aggregate; 2025 totals came in lower, and the 2026 weekly run rate is tracking lower still. Investors who need income and can accept capped upside in exchange for a rich yield are the right audience. FEPI is a poor proxy for owning the AI trade outright, because a plain covered-call Nasdaq strategy has delivered better total returns with less NAV drag, and simply owning QQQ has run circles around both.

Contact [email protected] for any questions or corrections.

© FangXiaNuo / iStock via Getty Images

Procter & Gamble (NYSE:PG | PG Price Prediction) and Colgate-Palmolive (NYSE:CL) both posted top and bottom line beats in their most recent quarters.

PG’s fiscal Q3 2026 leaned on Beauty and broad regional strength. Colgate’s Q1 2026 leaned on Latin America and Hill’s Pet. Same shelf, very different engines.

Beauty Powers P&G. Latin America Powers Colgate. P&G’s headline was breadth. Revenue of $21.23 billion rose 7.4% YoY, and every one of the five segments grew. Beauty led with 11% reported growth, powered by Hair Care, Skin Care and premium play SK-II, which the CFO said grew 18% overall with double-digit gains in China.

Core EPS of $1.59 beat consensus, the fourth straight quarter of doing so. The catch: core gross margin fell 100 basis points on tariffs and mix, and currency-neutral core EPS was flat.

Colgate’s story was geographic imbalance. Total revenue of $5.32 billion grew 8.4% YoY, with Latin America up 14.8% and Europe up 11.9%. North America went the other way, sliding 1.8% on a 3.2% volume decline.

CEO Noel Wallace said “North America was going to take some time” and pointed to late shelf resets and heavier competitor couponing. Hill’s Pet Nutrition kept humming, up 6.7% with a boost from Prime100.

One Reinvests Into Momentum. One Restructures Harder. CEO Shailesh Jejurikar said P&G is “increasing investments to accelerate momentum with consumers despite the challenging geopolitical and economic environment”.

That framing runs through Tide Evo, the biggest formula upgrade in 25 years, and Mr. Clean innovation delivering 18x fair share of bath cleaning category growth since launch. Tariffs sting to the tune of roughly $400 million after-tax, and management now guides to the low end of the $6.83 to $7.09 core EPS range.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and P&G didn't make the cut. Grab the names FREE today.

Business Driver P&G Colgate Main growth engine Beauty (Hair, Skin, SK-II) Latin America + Hill’s Pet Weak spot Grooming, Health Care volume North America volume Organic growth 3% 2.9% Colgate is choosing surgery. It expanded the SGPP restructuring to $350 to $550 million in cumulative pretax charges targeting $200 to $300 million in annual savings.

Gross margin guidance flipped from up to down thanks to $300 million in extra raw materials and logistics costs, with oil byproducts expected up more than 20% year over year. Advertising still climbed to $734 million, so Wallace is not starving the brands.

The Next Test Is Whether North America Wakes Up For Colgate, the whole thesis rides on U.S. shelves normalizing after late resets and on Hill’s holding its premium pricing. Shares are up 21.89% year to date, so the market has already granted some benefit of the doubt.

P&G’s next hurdle is different. Grooming and Health Care volumes need to turn, and the $1 billion pretax oil-linked headwind the CFO flagged will land mostly in Q4. Stock is up 7.18% YTD and still down 3.4% over the past year.

P&G as Ballast, Colgate as the Rebound Trade Setup P&G screens as the steadier of the two. The breadth of growth, all 10 categories and all 7 regions up, plus a 70th consecutive annual dividend increase, is the kind of consistency I want when tariffs and oil are wild cards.

For a turnaround profile, Colgate carries the more asymmetric setup. The North America drag is real, but Latin America is doing heavy lifting and the SGPP savings could compound if Wallace’s team executes. Both names get harder to underwrite if Brent sits near $110 for long.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and P&G didn't make the cut. Grab the names FREE today.

Contact [email protected] for any questions or corrections.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Medicare is not free, and the bill arrives every month for the rest of your life. The standard Part B premium in 2026 is $202.90 per month, which works out to roughly $2,435 a year per enrollee. Add Part D, a Medigap policy, and the occasional out-of-pocket charge, and most retirees end up writing checks closer to $5,000 a year per person for healthcare coverage they already “earned.”

How much capital, parked in income-producing investments, would cover that bill forever without touching principal?

The bill that never retires Retirees pay off mortgages. They sell the second car. Commuting costs vanish. Medicare premiums do not. They are deducted directly from Social Security, they rise almost every year, and they continue until death. The 2026 Part B premium jumped $17.90 from $185.00 in 2025, a roughly 10% increase in a single year, while the 2026 Social Security COLA came in at 2.8%. Healthcare inflation eats COLA for breakfast.

The math at three yield levels Using a $5,000 annual target (Part B plus Part D plus a modest Medigap plan), here is what the principal looks like:

3.5% yield needs about $143,000 in capital. This is the dividend-growth range. Think Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction), which just raised its quarterly payout to $1.34, marking 64 straight years of increases. The current yield sits near 2.2%, but the income compounds. 5% yield needs about $100,000. Realty Income (NYSE:O) pays monthly, currently $0.2705 a share, with a yield around 5.2%. NextEra Energy (NYSE:NEE) sits lower at 2.7% but is guiding to 10% dividend growth through 2026. 10% yield needs about $50,000. This is business development company, mortgage REIT, and covered-call ETF territory. The income is loud, the principal often shrinks. What freed-up cash actually buys Medicare premiums rarely feel expensive because they arrive a little at a time. Yet eliminating a $5,000 annual healthcare bill frees up money for things people actually notice. It can fund weekend trips, holiday travel, charitable giving, birthday gifts for grandchildren, dining out, hobbies, or the property tax bill on a paid-off home. Retirement often improves one recurring expense at a time, and Medicare is one of the largest recurring expenses most households face.

Why low yield often wins over twenty years Compare two portfolios sized to throw off $5,000 today.

Portfolio A: $143,000 at 3.5% yield, growing the payout 7% a year. Procter & Gamble (NYSE:PG) is the archetype, with 70 consecutive annual increases and a history reaching back to 1890. In ten years that $5,000 stream becomes roughly $9,800. In twenty, around $19,300.

Portfolio B: $50,000 at 10% yield, flat. Year one and year twenty both pay $5,000. Meanwhile, CPI has been running at roughly 0.5% a month, and healthcare inflation typically outpaces headline CPI. The bill keeps climbing while the check does not.

From Part B to the whole healthcare line item Part D adds another $40 to $70 a month for most enrollees, Medigap plans run $150 to $250, and the $283 Part B deductible resets every January. High earners with modified adjusted gross income above $109,000 individual or $218,000 joint pay IRMAA surcharges on top. A growing income stream that starts by covering Part B will, ten years out, cover most of the rest.

When this is the wrong project Earmarking six figures for Medicare premiums is the wrong call if you are 82 with limited assets, if you have higher-yield debt to retire, or if you need the cash for an upcoming surgery, a roof, or long-term care. Dedicated income portfolios reward time. Without it, the math does not pencil.

Three things to do this week Pull your last twelve months of Medicare expenses, not just Part B. That is your real target number. Compare the ten-year total return of a 3.5%-yielding dividend grower against a 10%-yielding income fund. The compounding gap is usually larger than expected. If you are within five years of enrolling, model IRMAA at your projected income bracket before you convert a traditional IRA to a Roth. Many retirees think of retirement income as one giant number. In practice, it is often easier to think in smaller pieces. First cover Medicare. Then utilities. Then property taxes. Over time, the portfolio stops feeling like an account balance and starts feeling like a quiet bill-paying machine.

Contact [email protected] for any questions or corrections.

© Michael Ciaglo / Getty Images News via Getty Images

Eli Lilly (NYSE:LLY | LLY Price Prediction) and Johnson & Johnson (NYSE:JNJ) just reported Q1 2026 results that read like two different playbooks for winning in healthcare. Lilly is riding a GLP-1 wave. JNJ is proving that a wide, refreshed portfolio can still compound. Both raised guidance and both are worth putting side by side right now.

GLP-1 Fireworks vs. a Deep Bench Lilly posted $19.80 billion in revenue, up 55.5% year over year, with Mounjaro alone contributing $8.66 billion and Zepbound adding $4.16 billion. That is a staggering concentration in metabolic drugs, and it delivered non-GAAP EPS of $8.55.

CEO David Ricks said “2026 is off to a strong start”, spotlighting the FDA approval of Foundayo, the first oral GLP-1 pill without food or water restrictions.

JNJ told a very different story. Revenue of $24.062 billion grew 9.9%, split between Innovative Medicine at $15.426 billion and MedTech at $8.636 billion. DARZALEX cleared $3.964 billion, TREMFYA jumped 68.3%, and cardiovascular MedTech rose 13% on Abiomed and Shockwave strength.

CEO Duato called the portfolio “unrivaled”, pointing to ICOTYDE, the first targeted oral peptide for plaque psoriasis.

Business Driver Eli Lilly Johnson & Johnson Main growth engine Mounjaro + Zepbound (GLP-1) Oncology + immunology switch to TREMFYA Biggest drag 13% price decline on rebates STELARA down 59.7% from biosimilars Q1 revenue growth 55.5% 9.9% One Company Concentrates, the Other Diversifies Lilly is doubling down on metabolic dominance. Ricks highlighted acquisitions of Orna, Centessa, Kelonia, and Ajax, plus a $6 billion Alabama plant and an NVIDIA (NASDAQ:NVDA) drug-discovery lab. Guidance now sits at $82 to $85 billion in revenue and $35.50 to $37 EPS. The trailing P/E of 42 reflects that ambition, and the stock is up 56.86% over the past year.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Eli Lilly didn't make the cut. Grab the names FREE today.

JNJ is sharpening focus by spinning off DePuy Synthes orthopaedics within 18 to 24 months. Full-year guidance climbed to $100.3 to $101.3 billion with adjusted EPS of $11.45 to $11.65. The dividend rose 3.1% to $1.34, marking 64 consecutive years of increases. Forward P/E of 22 and beta of 0.256 flag it as the calmer name.

What Could Break the Thesis Next For Lilly, watch how Foundayo ramps against injectable Zepbound and whether the 13% price decline keeps widening as Mounjaro enters China’s NRDL. PineBridge’s 2026 outlook flags lower-cost oral GLP-1 pills as the next expansion catalyst, which fits Lilly’s hand well. Reddit sentiment on LLY swung from a bullish score of 88 in early June to 22 by late June, so retail conviction is jumpy.

For JNJ, the STELARA cliff is real, but TREMFYA’s $1.608 billion quarter shows the handoff is working. Polymarket traders currently give a JNJ Q2 earnings beat only a 49% chance, so the July 15 report is a live wire.

Why I Would Own Both, for Different Reasons On growth exposure, Lilly screens as the more aggressive name. The GLP-1 category looks like a decade-long story, and Foundayo could pull in patients who never wanted an injection. That said, I do not love paying 33 times forward earnings for a business where two drugs drive the whole engine.

JNJ fits a different job in a portfolio: steadier compounding, a Dividend King record, and a MedTech kicker from VARIPULSE Pro and Shockwave. For readers focused on income and lower volatility, JNJ is the cleaner fit. For those willing to stomach GLP-1 headline risk, Lilly offers the more exciting slope. Owning a slice of each is arguably the easiest way to sleep at night.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Eli Lilly didn't make the cut. Grab the names FREE today.

Contact [email protected] for any questions or corrections.

Nvidia (NVDA 1.39%) needs no introduction. It's at the center of the artificial intelligence (AI) boom, supplying industry-leading hardware and software for the infrastructure build-out.

Investors might have heard of Strategy (MSTR +7.88%). It's a $32 billion enterprise software business that morphed into a Bitcoin treasury company.

Between these two stocks, whose recent performances are on opposite ends of the spectrum, which has a better chance of surging 10x by 2036?

Image source: The Motley Fool.

Nvidia's incredible financial gains have launched the stock Nvidia has been the most impressive story in the economy and stock market. Its shares are up an astonishing 897% in the past five years (as of June 30). When investors think of the AI revolution, there's no doubt this business is what comes to mind first. The company's financial success is impossible to overstate.

Just in the last three years, from Q1 2024 to the first quarter of fiscal 2027 (ended April 26), Nvidia's revenue soared 1,033%. Its graphics processing units, used to operate AI data centers, are perhaps the hottest piece of hardware the world has ever seen. Demand has been exceptional as Nvidia's hyperscaler customers race to build computing capacity to meet their clients' needs.

Phenomenal top-line growth has boosted the company's profit. Net income totaled $58.3 billion in the most recent fiscal quarter. That metric was just $2 billion exactly three years before, translating to a monster 29-fold three-year rise. Nvidia's pricing power plays a role here, as its gross margin was 74.9% during Q1.

Nvidia has a wide economic moat. The company clearly excels in hardware, but its CUDA software platform raises switching costs for developers. The combination of chips and dedicated software creates a robust ecosystem.

You're forgiven if you think this AI stock is extremely expensive. But it's not. Shares trade at a price-to-earnings ratio of 30.6. Considering Nvidia's unbelievable revenue and profit growth, this is an attractive entry point for interested buyers.

Today's Change

(

-1.39

%) $

-2.75

Current Price

$

194.84

Strategy continues to fine-tune its strategy Strategy is the single largest holder of Bitcoin in the world. As of June 30, the business held 847,363 units of the leading cryptocurrency on its balance sheet. This is a Bitcoin treasury company that provides leveraged exposure to the digital asset for its shareholders. So, the stock price is more volatile than the crypto. Strategy shares trade 82% below their peak, while Bitcoin is 52% off its record.

In a bull market, though, the company's stock is poised to be a monster winner. The digital asset reached an all-time high in October last year. In the five years leading up to that point, Strategy shares had skyrocketed 2,300%.

This company is not for faint-hearted investors. Shareholders are being tested right now, as Strategy's critics continue to question the sustainability of the business model.

To be clear, Strategy is not in a precarious financial position. The Bitcoin it owns is worth $49.6 billion, which equates to 28 times the company's annual combined dividend and interest obligations.

However, the management team is fine-tuning its operating playbook. It just announced a digital credit capital framework, with the main features allowing the business to repurchase its common stock and preferred shares and sell its Bitcoin stack when advantageous.

Strategy is a financial engineering machine. It funnels constantly debasing fiat currency into Bitcoin, a finite asset. The former depreciates perpetually, while the latter has appreciated tremendously in the past. Investors must believe that Strategy can take advantage of these contrasts to capture more value over time.

Today's Change

(

7.88

%) $

7.36

Current Price

$

100.75

Choose your level of risk and uncertainty If you're not bullish on Bitcoin, then you'll lean toward Nvidia. But the AI powerhouse isn't without its own set of risks. Uncertainty stems from a possible slowdown in AI spending, which could happen if enterprises don't see the returns they hoped for. Moreover, Nvidia's major customers are developing in-house chips to become self-reliant.

There's also risk and uncertainty regarding Bitcoin's long-term adoption, which isn't guaranteed, although I believe it has a bright future. And Strategy must operate with heightened focus on risk management.

Looking forward to a decade from now, I think Strategy has higher upside. This is supported by the view that it's a leveraged position tied to Bitcoin. Should the cryptocurrency's price rise 10-fold by 2036, a significantly smaller gain than what it achieved in the past 10 years, then Strategy should perform even better.

New York, New York--(Newsfile Corp. - July 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lucid Group, Inc. (NASDAQ: LCID) between February 25, 2026 and April 13, 2026, inclusive (the "Class Period"), of the important July 28, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Lucid securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Lucid class action, go to https://www.rosenlegal.com/cases/lucid-group-inc-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 28, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) a supplier quality issue had significantly disrupted deliveries of the Lucid Gravity; (2) the foregoing was likely to, and did, have a material negative impact on Lucid's business and financial results; (3) accordingly, the defendants had overstated the purported enhancements to Lucid's manufacturing and delivery capabilities and overall operations; and (4) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Lucid class action, go to https://www.rosenlegal.com/cases/lucid-group-inc-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/303841

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

New York, New York--(Newsfile Corp. - July 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Zoetis Inc. (NYSE: ZTS) between January 14, 2025 and May 6, 2026, inclusive (the "Class Period"), of the important July 27, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Zoetis securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Zoetis class action, go to https://rosenlegal.com/cases/zoetis-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 27, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and touted growing market share, strong veterinarian adoption, and accelerating sales growth across Zoetis' flagship Companion Animal products and/or failed to disclose that: (1) veterinarian prescription growth and adoption of Zoetis' Librela, a canine pain treatment, were sharply weakening as clinicians became more cautious following FDA safety warnings concerning serious neurological complications in dogs; (2) Zoetis' Simparica Trio was losing significant market share to a lower priced competing canine parasiticide with broader indicated use in a slowing overall market; and (3) Zoetis' dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Zoetis class action, go to https://rosenlegal.com/cases/zoetis-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/303851

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

The State Street Health Care Select Sector SPDR ETF (XLV +2.63%) provides broad, low-cost exposure to the entire healthcare sector, whereas the Invesco Pharmaceuticals ETF (PJP +2.84%) offers a concentrated bet on 29 specific pharmaceutical companies.

Investors seeking healthcare exposure often weigh broad-market efficiency against niche industry concentration. While both funds operate within the healthcare space, they differ significantly in their scope. The SPDR fund tracks a diversified index of large-cap healthcare stocks, while the Invesco fund homes in on the drug manufacturing and research segment.

Snapshot (cost & size)MetricPJPXLVIssuerInvescoSPDRShare price (as of June 30, 2026)$118.45$158.66Expense ratio0.57%0.08%1-yr return (as of June 30, 2026)49.9%19.8%Dividend yield0.9%1.6%Beta0.450.56AUM$353.9 million$40.9 billionBeta measures price volatility relative to the S&P 500; beta is calculated from five-year monthly returns. The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.

Cost is a major differentiator here; the State Street fund is significantly more affordable with an expense ratio of 0.08%. Additionally, it offers a higher payout for income seekers, with a yield gap of 0.70 percentage points over the Invesco ETF.

Performance & risk comparisonMetricPJPXLVMax drawdown (5 yr)(17.5%)(17.1%)Growth of $1,000 over 5 years (total return)$1,530$1,354What's insideThe SPDR ETF provides exposure across healthcare fields including biotechnology, life sciences, and health technology. Its largest positions include Eli Lilly (LLY +1.35%) at 16.72%, Johnson & Johnson (JNJ +3.35%) at 10.70%, and AbbVie (ABBV +3.90%) at 7.72%. The fund, which holds 59 securities, was launched in 1998. The SPDR ETF has paid $2.53 per share over the trailing 12 months, which on its recent ~$158.66 share price works out to a 1.6% yield.

Invesco’s ETF focuses specifically on 29 U.S. pharmaceutical companies involved in research, development, and distribution. Eli Lilly (5.22%), Abbott Laboratories (ABT +3.49%) (5.16%), and AbbVie (5.14%) are among its largest positions. The fund was launched in 2005. Invesco’s ETF has paid $1.06 per share over the trailing 12 months, which on its recent ~$118.45 share price works out to a 0.9% yield.

For more guidance on ETF investing, check out the full guide at this link.

What this means for investorsPerhaps the greatest difference between these two ETFs is that XLV is literally orders of magnitude larger than PJP in terms of assets under management. That size difference often has knock-on effects. For one, XLV has much higher average trading volume. Additionally, lower average volume for PJP means an increased likelihood of wider bid-ask spreads.

Overall, this seems like a situation where you're paying for your returns (although, as always, it's worth a reminder that past performance is no indication of future results). PJP has a higher expense ratio, but also higher one- and five-year returns. The choice is between PJP's better returns and higher expense ratio, or XLV's massively larger fund with greater liquidity and a bigger dividend yield. The former is probably more appealing to growth investors, while conservative types will likely prefer XLV.

Erin Kennedy has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie, Abbott Laboratories, and Eli Lilly. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

NiSource (NI) remains a 'buy' as its innovative data center agreements, notably with Amazon, position it for sustained growth and regulatory favor. NI's model isolates data center capex and returns, protecting existing customers from rate hikes while securing guaranteed returns and surcharges to reduce bills. With a $29B five-year capex plan and at least 8% projected EPS growth, NI offers a compelling blend of income and growth.

New York, New York--(Newsfile Corp. - July 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Graphic Packaging Holding Company (NYSE: GPK) between February 4, 2025 and February 2, 2026, inclusive (the "Class Period"), of the important July 6, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Graphic Packaging securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Graphic Packaging class action, go to https://rosenlegal.com/submit-form/?case_id=64523 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 6, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Graphic Packaging was experiencing, inter alia, significant inventory management issues, as well as significantly reduced demand and volumes and increased costs; (2) defendants downplayed the true scope and severity of the foregoing issues, which were likely to, and did, have a material negative impact on Graphic Packaging's business and financial results; (3) defendants likewise overstated the strength and sustainability of Graphic Packaging's business model and operations, as well as its ability to weather ongoing macroeconomic headwinds; (4) accordingly, Graphic Packaging's previously issued full year 2025 financial guidance was unreliable and/or unrealistic; and (5) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Graphic Packaging class action, go to https://rosenlegal.com/submit-form/?case_id=64523 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/303884

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us